Sign inCreate account

Report workspace

Add to folder
NCT00112983COMPLETEDanonymous

TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Sponsor

Source record

Jonsson Comprehensive Cancer Center

Phase

Source record

Phase 3

Modality

AI-normalized

protein therapy

Target

AI-normalized

Eculizumab targets the complement protein C5, inhibiting its cleavage and preventing the formation of the membrane attack complex, thereby reducing hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Indication / condition

AI-normalized

Leukemia

Intervention

Source record

eculizumab

Source & freshness

Source record

NCT ID

NCT00112983

Original source

ClinicalTrials.gov

Source last updated

May 30, 2013

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00112983

Title

TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Sponsor

Jonsson Comprehensive Cancer Center

Status

COMPLETED

Phase

Phase 3

Condition raw

Leukemia

Condition normalized

Leukemia

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

Eculizumab targets the complement protein C5, inhibiting its cleavage and preventing the formation of the membrane attack complex, thereby reducing hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Target normalized

Eculizumab targets the complement protein C5, inhibiting its cleavage and preventing the formation of the membrane attack complex, thereby reducing hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Interventions

eculizumab

Public preview

Source record

The TRIUMPH trial evaluates eculizumab's efficacy in reducing transfusion requirements and stabilizing hemoglobin levels in PNH patients, a condition with significant unmet medical needs. The successful outcome of this trial could reinforce eculizumab's position in the market, potentially expanding its label indications and increasing market share in the rare disease segment. Given the high cost of eculizumab and the limited competition in the PNH space, positive results may lead to increased revenue streams for the sponsor, Jonsson Comprehensive Cancer Center, and its collaborators. Stakeholders should consider the implications of trial outcomes on pricing strategies and market access, particularly in regions with stringent reimbursement frameworks.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

TRIUMPH: A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT00112983

Status

COMPLETED

Phase

Phase 3

Sponsor

Jonsson Comprehensive Cancer Center

Executive brief

Investment-Ready Snapshot

The TRIUMPH trial evaluates eculizumab's efficacy in reducing transfusion requirements and stabilizing hemoglobin levels in PNH patients, a condition with significant unmet medical needs. The successful outcome of this trial could reinforce eculizumab's position in the market, potentially expanding its label indications and increasing market share in the rare disease segment. Given the high cost of eculizumab and the limited competition in the PNH space, positive results may lead to increased revenue streams for the sponsor, Jonsson Comprehensive Cancer Center, and its collaborators. Stakeholders should consider the implications of trial outcomes on pricing strategies and market access, particularly in regions with stringent reimbursement frameworks.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 30, 2013
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00112983

Indication

Leukemia

Modality

protein therapy

Target

Eculizumab targets the complement protein C5, inhibiting its cleavage and preventing the formation of the membrane attack complex, thereby reducing hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).

Intervention

eculizumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.